Inhalation CDMO Vectura has announced the resignation of Aerami CEO Anne Whitaker from Vectura’s board of directors “in light of potential conflicts that could arise in the future as a result of her role of Chief Executive Officer at Aerami Therapeutics.”
In June 2020, Vectura and Aerami announced a partnership agreement for development of inhaled imatinib (VR325) for the treatment of pulmonary arterial hypertension (PAH), with Aerami agreeing to purchase Vectura’s Fox nebulizer devices under the terms of the deal. Prior to its 2019 transformation from an inhaled drug developer to a CDMO, Vectura was developing VR325 on its own.
Vectura Chairman of the Board Bruno Angelici said, “I would like to thank Anne for her significant contributions to Vectura since her appointment in June 2018. On behalf of the all the board, I wish her every success in her continuing role at Aerami Therapeutics and for the future.”
Whitaker joined Dance Biopharm as CEO in September 2018 (Dance changed its name to Aerami in September 2019). She commented, “I have thoroughly enjoyed my role on the board of Vectura and am very grateful to Bruno and the entire management team and board for the opportunity. Vectura is extremely well-positioned for the future as a CDMO and I look forward to seeing the company achieve success with partnering with pharmaceutical and biotech companies to make a difference for patients.”
The company added that, “The Nomination Committee has initiated steps to seek an appropriate additional Independent Non-Executive Director and will take diversity matters fully into account when reviewing candidates for this appointment.”
Read the Vectura press release.
